Summary The pattern of TGFP expression and in vitro response to TGFP has been defined in three ovarian carcinoma cell lines (PEOl, PE04 and PE014). Marked (Colletta, 1990) . Research into the biological role of TGFP's is complicated by the diversity of the peptide family, with at least three TGF-,B peptides being identified thus far in the human (Derynck et al., 1985; Arrick et al., 1990) and additional forms being present in other species (Roberts et al., 1990b) . However, TGFIB has been detected in a wide range of tissues, including transformed cells (Roberts et al., 1981) , and dependent upon conditions it may be either stimulatory or inhibitory for cell growth (Roberts et al., 1985) . There are multiple binding proteins for TGFPI's (Frolik et al., 1984; Massague & Like, 1985; Massague et al., 1990) and recent data suggest that the growth regulatory effects of TGFP may be dependent upon the presence of specific classes of binding proteins (Roberts, 1991 
The transforming growth factors are increasingly recognised as important molecules in the regulation of cell growth and differentiation (Nilsen, 1990; Barnard et al., 1990 for reviews). Whilst the role of TGF-x has been relatively widely studied, data on the TGFP's are only now becoming available. These peptides are generating interest in a variety of fields including development (Akhurst et al., 1990; Roberts et al., 1990a) , bone remodelling (Noda & Rodan, 1989; Bonewald & Mundy, 1990) , extracellular matrix production (Roberts & Sporn, 1989) and the prevention and treatment of cancer (Colletta, 1990) . Research into the biological role of TGFP's is complicated by the diversity of the peptide family, with at least three TGF-,B peptides being identified thus far in the human (Derynck et al., 1985; Arrick et al., 1990) and additional forms being present in other species (Roberts et al., 1990b) . However, TGFIB has been detected in a wide range of tissues, including transformed cells (Roberts et al., 1981) , and dependent upon conditions it may be either stimulatory or inhibitory for cell growth (Roberts et al., 1985) . There are multiple binding proteins for TGFPI's (Frolik et al., 1984; Massague & Like, 1985; Massague et al., 1990) and recent data suggest that the growth regulatory effects of TGFP may be dependent upon the presence of specific classes of binding proteins (Roberts, 1991 ).
TGFP appears to play a role in normal ovarian function, particularly in the regulation of granulosa cell functions in response to follicle stimulating hormone (Adashi et al., 1989 
Cell lines
The human ovarian carcinoma cell lines PEO1, PEO4 and PEO14 were established and characterised as previously described (Langdon et al., 1988) . They were maintained routinely at 37'C in a humidified atmosphere of 5% CO2 in air in RPMI 1640 (Gibco) supplemented with Streptomycin (100 ILg ml '), Penicillin (100 IU ml-') and glutamine (2 mM; 'RPMI') and containing 5% non-charcoal stripped heatinactivated foetal calf serum (FCS Synthesis of riboprobes Labelled RNA was prepared from linearised template DNA using a Gemini II system (Promega Ltd, Southampton, UK).
Template DNA was incubated in the presence of an RNAase inhibitor (Human placental RNAsin; Amersham plc), cold ribonucleosides, dithiothreitol and 32P-rCTP with the appropriate RNA polymerase (T3, T7 or SP6) for 1 h at 37°C. The DNA template was then removed by incubation with RQ1 DNAase (Promega Ltd) for 15 min at 37°C. Labelled RNA was precipitated in the presence of added tRNA (Sigma) as carrier and full length transcripts were isolated by polyacrylamide electrophoresis. Following identification of full length transcripts by autoradiography, the bands were excised and labelled RNA eluted from the gel, precipitated under ethanol and resuspended in hybridisation buffer prior to use in RNAase protection assays.
RNAase protection assay
Test RNA (20 rig) was precipitated under ethanol, dried and resuspended in 30 gAl hybridisation buffer (80% formamide, 40 mM Pipes (pH 6.7), 400 mM NaCl, 1 mM EDTA); tRNA was prepared in a similar manner as a negative control. Test probe (106 c.p.m.) plus actin probe (106 c.p.m.) were added to each sample. Samples were incubated at 85°C for 20 min, transferred to a water bath and left to hybridise overnight at 51°C. After hybridisation, single stranded RNA (both labelled and cold) was removed by incubating with single strand specific RNAases A and TI (Boehringer Mannheim) at 37°C for 30 min, followed by incubation with proteinase K in SDS at 37°C for 15 min. Protein was extracted by using phenol/ chloroform-isoamyl alcohol. is shown in Figure 4 , significant inhibitory effects were produced at day 6 but not day 3 by addition of 1 ng ml1' TGFPI in HITS and 0. PE014 In contrast to PEOI and PE04, TGFPI3 produced a significant inhibitory effect on the growth of PE014 in each of the culture conditions tested. The effects were dose related and were more pronounced after 6 days of culture. At the highest doses of TGFi, growth was significantly inhibited during the first 3 days of exposure of the cells (P<0.05) whilst by 6 days after initial exposure growth inhibition was produced by all doses above 0.01 ng ml-' reaching a maximum at 1 ng ml-' TGFI (P <0.05; Figure 5 ). These effects of TGFP, occurred irrespective of the presence or concentration of serum and were consistent in each of three replicate experiments (representative experiment shown; Figure 5 ).
The effects observed with TGFPi2 on the cell line PE014
were similar but less marked than those found with TGF,I,. Thus higher concentrations of TGFP2 were required for significant effects to be demonstrated and the degree of inhibition was less pronounced, nevertheless the observed effects were consistent in each of three replicate experiments (representative experiment shown; Figure 6 ). Figure 7 ). The responses observed for the ovarian carcinoma cell lines investigated here contrast with those observed previously (Marth et al., 1990) in which all four cell lines tested were inhibited by TGFP2, but the concentrations used were up to 100-fold higher than those used in the present study. None of the inhibitory doses used in the present study would have been effective on these previously tested cell lines (Marth et al., 1990) . It = untreated cells, 1 = cells exposed to 0.01 ng ml-' and m = cells exposed to 0.1 ng ml-; = cells exposed to 0.5 ng ml-' and = = cells exposed to 1.Ongml-' TGFP, respectively over either 3 or 6 days. * = Statistically significant difference with respect to time matched control (P<0.05). a, Cells grown in RPMI containing HITS. b, Cells grown in RPMI containing 0.5% DCS FCS. c, Cells grown in RPMI containing 5% DCS FCS (see text for details). sitivity to TGFP's being over 100 times more sensitive to TGFPI, than other cell lines reported. Treatment with doses of TGFP between of 0.1 and 1 ng ml', reduced cell proliferation by up 50%.
It has recently been suggested that the growth inhibitory effects of the TGFI3 family results in an arrest of cells in the GI phase of the cell cycle (Roberts et al., 1991) . The data obtained for the PE014 cell line support this observation.
Thus within 24 h of administration of either TGFP, or TGFP2 the proportion of cells in the S phase of the cycle was markedly reduced, with a concomitant increase in cell numbers in the GO/GI phase of the cell cycle. By 48 h post TGFP administration cell numbers in both the S phase and the G2/M phases of the cell cycle were reduced, with a further rise in the proportion of cells in the GO/GI phase of the cell cycle being observed (Figure 7) . These data suggests that any effect on cell division exerted by the TGFPI family probably occurs in the early part of the cell cycle. In addition to the growth inhibitory effects of TGFP's being targeted primarily in the GI phase of the cycle, data exists which suggests that such effects are mediated via type II binding sites for TGFP's on the cell surface (Roberts et al., 1991) . It has been demonstrated (Massague et al., 1990) TGFP,. Further studies to define the level of peptide production to establish the presence of TGFP binding proteins and examine the effects of TGFP blocking antibodies would be of interest in determining the relative role of the different forms of TGFPI and their binding proteins in these putative autocrine pathways. TGFPi has been shown to be an autocrine regulator of breast cancer cells (Arteaga et al., 1988) and in lymphocyte activation (Lucas et al., 1990 ) but this loop had not been previously established for ovarian carcinomas. In breast cancer, secretion of TGFP occurs under steroid hormone regulation (Knabbe et al., 1987; Colletta, 1991) , therefore to demonstrate the presence of mRNA for TGFP cells were grown in the presence of non-charcoal stripped serum. The physiological and clinical relevance of these findings remain to be elucidated, however it is known that (1) TGFP may be a marker of progression to steroid insensitivity in breast cancer cells (Daly & Darbre, 1990) . (2) TGFP has been implicated in the autocrine regulation of normal ovarian function (Knecht et al., 1987; Kim & Schomberg, 1989; Magoffin et al., 1989) , and (3) TGF beta has been implicated in the process of metastasis (Schwarz et al., 1990 suggest that these factors may play distinct roles in the regulation of cell division.
